

# Anti-HIV Mixed Subtype Panel

**REF** Catalogue No: MSP-HIV-001

The Biomex GmbH Anti-HIV Mixed Subtype Panel consists of 22 members with each member containing 0.5 mL of human plasma. 17 individuals feature Human Immunodeficiency virus group M traits, one individual group O, two individuals feature HIV 2 and two are negative to HIV.

## 1. Intended Use

This Mixed Subtype Panel (MSP) is intended for standard testing by diagnostic manufacturers and researchers during assay development, evaluation, troubleshooting and post-marked surveillance of IgG antibody test systems and methods. Moreover, it serves as validation tool for diagnostic specificity, determination of analytical sensitivity or for the identification of cut-off values.

## 2. Storage and Stability

Store the MSP at -20°C to -80°C. Thaw samples at room temperature and mix gently by inversion before usage. Avoid foaming, contamination and repeated freeze and thaw cycles. After usage, return immediately to storage conditions.

## 3. Warnings and Precautions

Potentially infectious materials. Handle the product as if capable of transmitting infectious diseases. Do not pipette by mouth.

### Prevention:

P264: Wash hands thoroughly after handling.

P270: Do not eat, drink or smoke when using this product

P273: Avoid the release to the environment

### Disposal:

P501: Dispose of waste in accordance to applicable local or national regulations. Waste must be disposed in a secured manner.

## 4. Donor Information

All panel members have been tested and found negative/non-reactive for anti-HCV, HBsAg and Syphilis with CE marked tests.







## 5. Detection Methods

Each panel member is assayed for HIV antibodies with Abbott ARCHITECT® HIV Ag/Ab combo assay kit, Abbott PRISM® HIV Ag/Ab combo assay kit, HCV and HBsAg. Testing is performed with CE marked test.

## 6. Limitations and Restrictions

This panel is for Research Use Only and not intended for human or animal diagnostics, or for therapeutic purposes. Each laboratory has the responsibility to ascertain the suitability of the MSP for its particular application and to establish their own guidelines for interpretation of results. Data is provided for informational purposes only. The Biomex GmbH does not claim that others can duplicate these test results exactly.

Declaration of used symbols

|   |   |   |   |   |   |
|---|---|---|---|---|---|
|  |  |  |  |  |  |
| Catalog Number  | Lot Number  | Warning   | Consult Instructions for Use  | Manufactured by   | Temperature Limitation  |

## Anti-HIV Mixed Subtype Panel, Catalogue No: MSP-HIV-001

| Panel Member | Bleed Date | Age | Gender | Specification | Group | Subtype   | ABBOTT ARCHITECT® HIV Ag/Ab Combo Assay | ABBOTT PRISM® HIV Ag/Ab Combo Assay |
|--------------|------------|-----|--------|---------------|-------|-----------|---|-------------------------------------|
|              |            |     |        |               |       |           | S/Co                                    |                                     |
| 1            | 19.11.2010 | 24  | M      | HIV 1         | M     | A1        | 405.3                                   | pos.                                |
| 2            | 19.07.2007 | 51  | W      | HIV 1         | M     | A1        | 743.6                                   | pos.                                |
| 3            | 16.09.2010 | 57  | M      | HIV 1         | M     | B         | 726.9                                   | pos.                                |
| 4            | 08.09.2010 | 48  | M      | HIV 1         | M     | B         | 945.4                                   | pos.                                |
| 5            | 07.03.2007 | 34  | W      | HIV 1         | M     | C         | 707.7                                   | pos.                                |
| 6            | 14.02.2007 | 28  | W      | HIV 1         | M     | C         | 780.6                                   | pos.                                |
| 7            | 07.08.2010 | 31  | M      | HIV 1         | M     | D         | 720.2                                   | pos.                                |
| 8            | 26.08.2010 | 49  | M      | HIV 1         | M     | D         | 227.0                                   | pos.                                |
| 9            | 26.02.2007 | 41  | M      | HIV 1         | M     | F1        | 464.0                                   | pos.                                |
| 10           | 03.11.2010 | 36  | W      | HIV 1         | M     | G         | 799.3                                   | pos.                                |
| 11           | 10.10.2010 | 49  | W      | HIV 1         | M     | K         | 482.6                                   | pos.                                |
| 12           | 19.01.2007 | 39  | M      | HIV 1         | M     | CRF01-AE  | 487.4                                   | pos.                                |
| 13           | 27.02.2007 | 46  | M      | HIV 1         | M     | CRF01-AE  | 159.5                                   | pos.                                |
| 14           | 14.10.2010 | 36  | M      | HIV 1         | M     | CRF02-AG  | 925.9                                   | pos.                                |
| 15           | 28.07.2007 | 41  | W      | HIV 1         | M     | CRF02-AG  | 510.8                                   | pos.                                |
| 16           | 01.08.2010 | 28  | M      | HIV 1         | M     | CRF03-AB  | 538.7                                   | pos.                                |
| 17           | 20.08.2007 | 38  | M      | HIV 1         | M     | CRF11-cpx | 591.7                                   | pos.                                |
| 18           | 25.10.2009 | 36  | W      | HIV 1         | O     | -         | 7.8                                     | pos.                                |
| 19           | 11.04.2010 | 25  | M      | HIV 2         | -     | A         | 226.4                                   | pos.                                |
| 20           | 11.04.2010 | 45  | M      | HIV 2         | -     | A         | 176.9                                   | pos.                                |
| 21           | 17.12.2010 | 18  | W      | Negative      | -     | -         | -                                       | neg.                                |
| 22           | 01.02.2011 | 22  | W      | Negative      | -     | -         | -                                       | neg.                                |